Background: Oral menopausal hormone therapy causes venous thrombosis but
| INTRODUC TI ON
Oral menopausal hormone therapy (HT) increases the risk of venous thrombosis (VT). 1, 2 As this treatment provides effective relief of menopausal symptoms and VT is the most common adverse vascular outcome of HT, knowledge of susceptibility factors might assist women and their physicians in decision-making on risks and benefits of HT use.
In perimenopausal women, the annual rate of VT is 1-2 per 1000, 3 which rises to 0.5-1% over 5 years of HT use. In the Women's Health Initiative (WHI) trials women who were older, obese, or had factor V Leiden were at higher risk of VT with HT. 1, 2 For example, conjugated equine estrogens plus medroxyprogesterone acetate (E+P) doubled the risk of VT overall but in women with factor V Leiden the risk was increased 6.7-fold, predicting a cumulative incidence of 3.3-6.7%
over 5 years of HT use. Other hemostatic disorders associated with VT risk might predict susceptibility for HT-related VT, as might HTinduced changes in hemostasis or inflammation factors. [4] [5] [6] [7] We hypothesized that levels of hemostasis factors and C-reactive protein (CRP), an inflammation marker, would be associated with risk of VT with HT in the WHI trials, and that changes in some of these factors while on treatment would be associated with increased risk of VT.
We conducted a case-control study nested in the two WHI hormone trials. We measured biomarkers of thrombosis risk (factors VIIc, VIIIc, and IXc, von Willebrand factor, fibrinogen, protein C, protein S, antithrombin, prothrombin, D-dimer, and CRP) and others that are altered by HT but have no or uncertain associations with VT (plasminogen activator inhibitor-1 [PAI-1], prothrombin fragment
1.2, plasmin antiplasmin complex [PAP]). Associations of one-year
HT-induced changes in some of these biomarkers with risk of VT were also studied.
| METHODS
The study design was a nested case control study embedded in two randomized controlled trials of hormone use versus placebo (clinicaltrials.gov identifier NCT 00000611; Women's Health Initiative).
| Subjects
Detailed descriptions and results of the WHI hormone trials, including Consolidated Standards of Reporting Trials diagrams, were previously published. [8] [9] [10] [11] Eligible postmenopausal women aged 50-79 years were enrolled in 1993-1998. Exclusion criteria related to safety concerns with HT. Methods were approved at each site by institutional review committees, and participants provided written informed consent.
The WHI hormone trials included 16 608 women with an intact uterus who were randomly assigned in double-blind fashion
to receive E + P or identical placebo, and 10 739 women without a uterus who were randomized to E or placebo. Treatment included one daily tablet containing 0.625 mg conjugated equine estrogen with or without 2.5 mg medroxyprogesterone acetate or identical placebo. At baseline and one year later, blood was drawn and stored at −70 °C.
hormone use were not significant on the multiplicative scale. Considering a multimarker score of eight biomarkers, women with three or more abnormal biomarkers had 15.5-fold increased odds of VT (95% CI 6.8-35.1). One-year changes in biomarkers were not robustly associated with subsequent thrombosis risk.
Conclusion:
Abnormal levels of biomarkers of thrombosis risk identified women at increased risk of future venous thrombosis with oral menopausal hormone therapy.
Findings support the potential for clinical use of D-dimer testing in advance of hormone therapy prescription.
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Essentials
• Venous thrombosis is the most common vascular complication of menopausal hormone use.
• We studied biomarkers to predict thrombosis with hormones in the Women's Health Initiative.
• Lower proteins C and S, and higher D-dimer were related to thrombosis risk.
• The 25% of women with high D-dimer had a six-times greater risk of thrombosis with hormones.
Race/ethnicity was self-reported using a list and categorized as black or white/other. Body mass index (BMI) was measured to define overweight (BMI 25-30 kg/m 2 ) and obesity (BMI >30 kg/m 2 ).
| Events ascertainment
Participants were queried every 6 months for possible VT. Hospital discharge summaries were reviewed at each clinical center for all overnight hospitalizations except selected elective procedures.
Outpatient-treated VT events were ascertained starting in 1999 by investigating self-reports of participants. Validation of potential VT events was done as previously described. 9 Validated deep vein thrombosis (DVT) was based on a physician diagnosis and positive findings on doppler or duplex ultrasound, or rarely venogram, plethysmography, isotope scan, or at autopsy. Validated pulmonary embolism (PE) was based on a discharge summary diagnosis of PE and positive findings on ventilation-perfusion lung scan, pulmonary angiogram, computed tomography, or at autopsy.
| Nested case control study
Among all trial participants, excluding baseline warfarin users, a nested case control study of biomarkers in relation to VT, stroke, and myocardial infarction occurring between randomization and February 28, 2001 was conducted. One control was selected for each case with matching on age, randomization date and prevalent vascular disease (myocardial infarction, stroke, or VT). In this study we utilized data from the 215 VT cases and all selected controls (867 total controls). 
| Laboratory analysis

| Statistical analysis
Data from both trials were combined for primary analysis.
Separate analyses by trial were completed secondarily. For baseline biomarkers in cases and controls, skewed distributions were log-transformed to achieve a normal distribution and geometric means were reported. Hormone therapy use was based on intention-to-treat.
Logistic regression, adjusting for age, race, BMI, treatment assignment, pre-baseline self-reported VT, and hysterectomy status, was used to determine odds ratios of VT for abnormal levels of each biomarker compared to normal levels. Cutoff levels for most biomarkers were defined a priori based on the literature with values shown in the footnote to Table 1 . For the following biomarkers, since there is no evidence on VT to suggest cutoffs for abnormal values a priori, we selected the following cutoffs: fragment 1.2 and PAI-1 > 90th percentile, and for antithrombin, protein C and free and total protein S values less than the 5th percentile. Assessments for linear association were also made using each biomarker or its log transformed distribution treated as a continuous variable. We determined the association of each woman's number of abnormal biomarkers with VT risk, including previously published data for factor V Leiden.
The additive risk of VT with abnormal biomarkers and HT was assessed by cross-classifying women by treatment assignment and whether they had an abnormal level of each biomarker. To examine change in biomarker levels in HT compared to placebo recipients, linear regression was used comparing treatment groups, adjusting for age, race, BMI, pre-baseline VT, and hysterectomy status.
| RESULTS
With mean follow up of 4.1 years, 215 women had VT, 69 in the E trial and 146 in the larger E+P trial. There were 359 and 508 controls selected in each trial. Among cases, 59% in the E trial and 54% in the E+P trial had DVT without PE, with the remainder having PE. There were 132 women with VT after the one-year follow up phlebotomy. Table 2 shows baseline characteristics by case-control status. Few women had pre-baseline self-reported VT. Cases had higher mean BMI, higher prevalence of pre-baseline VT, and higher mean baseline levels of factor VIII, von Willebrand factor, D-dimer, fragment 1.2, and CRP than controls and slightly lower protein C, antithrombin and free protein S. These differences were similar considering the trials separately, but in the E+P trial, cases had similar free protein S levels as controls. When the activation markers D-dimer, F1.2 and PAP were included together in the same model, the odds ratios of VT for each of these were 2.7 (95% CI 1.9-4.0), 1.6 (95% CI 1.0-2.6) and 2.1 (95% CI 1.3-3.5), respectively.
| Baseline characteristics
| Associations of biomarkers with VT
None of the above results differed materially comparing the two trials (data not shown).
| Joint associations of HT and abnormal biomarkers with VT
To evaluate whether abnormal biomarkers were susceptibility factors for HT-related VT, women were cross-classified by treatment assignment and whether they had an abnormal biomarker and odds ratios for VT calculated for exposed groups compared to women randomized to placebo with a normal biomarker (Table 3 ).
In general, HT in the absence of an abnormal biomarker was associated with a 2-2.5-fold increased risk of VT, while women with abnormal biomarkers assigned to placebo had a 1.0-to 6.5-fold in- 
| Change in biomarkers
The one-year changes in biomarkers in each trial by case-control status, excluding women who had VT in that year, are shown in Supplemental One-year changes in biomarkers with treatment compared to placebo were generally similar for E and E+P (Supplemental Table B ).
In the combined trials, fibrinogen, PAI-1 and antithrombin declined with HT compared to placebo while PAP and CRP increased and the other factors did not change. Table 4 shows associations of quartiles of change in biomarkers with odds of VT after the second blood collection. Compared to women in the first quartile of change in each biomarker, women in the top quartile of change in prothrombin, factor VIII, von Willebrand factor, fragment 1.2, PAP, and CRP were at increased risk of subsequent VT. While the 95% confidence intervals for these odds ratios all included 1.0, PAP and CRP change in the top compared to bottom quartile were associated with a 1.9-fold increased risk. Considering the biomarkers as continuous variables, only larger increases in factor VIII were associated with subsequent VT; the odds ratio of VT for a 32% greater one-year increase of factor VIII (1 SD increment) was 1.3 (95% CI 1.1-1.6). Interpretation of results did not differ materially considering the trials separately (data not shown).
| DISCUSSION
| Main findings
In this study some thrombosis biomarkers were susceptibility factors for HT-associated VT, especially higher baseline D-dimer, which was associated with 6-fold increased odds of VT with HT. This risk increase is comparable to that of the combination of factor V Leiden and HT previously reported in these trials. 
| Relation to other work
Venous thrombosis is a common serious vascular complication of menopausal HT and limited studies suggest the risk is higher in women who are older, obese or have factor V Leiden, prothrombin 20210A or non-O blood group. 1, 2, [16] [17] [18] [19] In contrast to literature for oral contraceptives, despite many studies on effects of HT on hemostasis factors, 7 we are aware of no other prospective studies on biomarkers related to VT risk (or their changes on treatment) as predisposing factors for HT-related VT. BMI, body mass index; CI, confidence interval; HT, hormone therapy; P, percentile; PAP, plasmin antiplasmin complex; VT, venous thrombosis. a Women were cross classified for their level of each hemostatic factor (cutoffs provided in Table 2 footnote) and treatment assignment, and each group was compared using logistic regression models to those randomized to placebo and who had normal levels of each factor. Models were adjusted for age, race, BMI, treatment assignment, self-reported VT, and hysterectomy status at screening. P-values for multiplicative interaction between treatment assignment and abnormal biomarkers were all >.05.
| Potential implications of the findings
(Continues)
TA B L E 3 (Continued) stroke and coronary heart disease and, among a variety of biomarkers, only the change in D-dimer with HT predicted stroke risk (but not coronary risk) during follow-up. 26, 27 Considering possible clinical application of D-dimer testing, the threshold value defining VT risk in this study is similar to the thresh- TA B L E 4 (Continued) (Continues) study of their relationships with VT risk in healthy populations is indicated. Similar to another study, 30 we were unable to confirm previous findings that higher factor IX is a VT risk factor. 31, 32 We also did not confirm prior conflicting reports of an association of PAI-1 with VT risk. 28, 33 Lack of association of well-established VT risk factors, higher factor VIIIc and von Willebrand factor with odds of VT here was unexplained, and these were associated with stroke and coronary risk in our study.
26,27
| Study limitations
Limitations of this study require consideration. Participants were older than women who would currently be considering starting
HT. There was some nonadherence to assigned treatment in both placebo and HT groups, 11 
| Study strengths
The key strength of the study was the evaluation of participants from a rigorously conducted randomized controlled trial, eliminating selective prescribing of HT. In addition, we used baseline blood samples prior to HT use or VT for measurement of biomarkers. We are not aware of an existing or planned study with similar design that could be used for replication or which might overcome the limitations mentioned above.
| CONCLUSIONS
The 
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